MARK2 and melanoma: Supporting this, the adenyl cyclase gene, ADCY9, and the PKA catalytic subunit alpha (PRKACA) were identified as key resistance effectors in melanoma, with PRKACA displaying the highest rescue score among serine/threonine kinases in a gain-of-function resistance study (Johannessen et al., 2013).